Julio C Delgado
Overview
Explore the profile of Julio C Delgado including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
888
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Ravkov E, Ventura M, Gudipaty S, Ng D, Delgado J, Lin L
Cytometry B Clin Cytom
. 2024 Sep;
108(1):67-76.
PMID: 39287115
HLA-B27 is a major histocompatibility complex (MHC) class I antigen which exhibits strong association (90%) with ankylosing spondylitis. HLA-B27 detection in patients by flow cytometry is a widely used clinical...
3.
Ravkov E, Williams E, Elgort M, Barker A, Planelles V, Spivak A, et al.
Front Immunol
. 2024 Jan;
14:1329026.
PMID: 38250080
Introduction: The clinical manifestations of acute severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) suggest a dysregulation of the host immune response that leads...
4.
Ravkov E, Williams E, Elgort M, Barker A, Planelles V, Spivak A, et al.
bioRxiv
. 2023 Nov;
PMID: 37961575
The clinical manifestations of acute severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and COVID-19 suggest a dysregulation of the host immune response that leads to inflammation, thrombosis, and...
5.
Jain D, Pido M, Delgado J, Willrich M, Lazar-Molnar E
J Appl Lab Med
. 2023 Sep;
8(6):1054-1064.
PMID: 37658801
Background: Adalimumab is a fully human monoclonal antibody developed against tumor necrosis factor (TNF), used for the treatment of autoimmune and chronic inflammatory diseases. Immunogenicity to this drug may lead...
6.
Hartsell J, Leung D, Zhang Y, Delgado J, Alder S, Samore M
PeerJ
. 2023 Jul;
11:e15247.
PMID: 37483960
Background: This study evaluated the discordance between Abbott Architect SARS-CoV-2 IgG and EUROIMMUN SARS-COV-2 ELISA in a seroprevalence study. Methods: From June 10 to August 15, 2020, 8,246 specimens were...
7.
Kim S, Yao Z, Marsh M, Eckert D, Kay M, Lyakisheva A, et al.
Nat Commun
. 2022 Jul;
13(1):3716.
PMID: 35778399
The COVID-19 pandemic triggered the development of numerous diagnostic tools to monitor infection and to determine immune response. Although assays to measure binding antibodies against SARS-CoV-2 are widely available, more...
8.
Nelson H, Genzen J, Delgado J, Rudolf J
J Appl Lab Med
. 2021 Dec;
7(2):622-625.
PMID: 34849974
No abstract available.
9.
Nandakumar V, Profaizer T, Lozier B, Elgort M, Rychert J, Slev P, et al.
J Appl Lab Med
. 2021 Nov;
7(3):698-710.
PMID: 34741514
Background: Numerous serology assays are available for detection of SARS-CoV-2 antibodies but are limited in that only 1 or 2 target antigen(s) can be tested at a time. Here, we...
10.
Samore M, Looney A, Orleans B, Greene T, Seegert N, Delgado J, et al.
Emerg Infect Dis
. 2021 Sep;
27(11):2786-2794.
PMID: 34469285
We aimed to generate an unbiased estimate of the incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in 4 urban counties in Utah, USA. We used a multistage...